|
MX391051B
(es)
|
2014-12-30 |
2025-03-21 |
Celgene Corp |
Anticuerpos anti-cd47 y usos de los mismos.
|
|
WO2017053423A1
(en)
|
2015-09-21 |
2017-03-30 |
Erasmus University Medical Center |
Anti-cd47 antibodies and methods of use
|
|
US11560433B2
(en)
|
2016-05-27 |
2023-01-24 |
Albert Einstein College Of Medicine |
Methods of treatment by targeting VCAM1 and MAEA
|
|
CN109689684B
(zh)
*
|
2016-07-06 |
2022-09-23 |
细胞基因公司 |
具有低免疫原性的抗体及其用途
|
|
CN117717604A
(zh)
|
2016-07-19 |
2024-03-19 |
梯瓦制药澳大利亚股份有限公司 |
抗cd47联合治疗
|
|
AU2017332960B2
(en)
|
2016-10-20 |
2019-09-12 |
I-Mab Biopharma Us Limited |
Novel CD47 monoclonal antibodies and uses thereof
|
|
EP3529276A4
(en)
|
2016-10-21 |
2020-06-17 |
Arch Oncology, Inc. |
CD47 THERAPEUTIC ANTIBODIES
|
|
CA3042581A1
(en)
*
|
2016-11-03 |
2018-05-11 |
Trillium Therapeutics Inc. |
Enhancement of cd47 blockade therapy by proteasome inhibitors
|
|
CA3042583A1
(en)
|
2016-11-03 |
2018-05-11 |
Trillium Therapeutics Inc. |
Improvements in cd47 blockade therapy by hdac inhibitors
|
|
GB201700621D0
(en)
|
2017-01-13 |
2017-03-01 |
Guest Ryan Dominic |
Method,device and kit for the aseptic isolation,enrichment and stabilsation of cells from mammalian solid tissue
|
|
US20190309066A1
(en)
*
|
2017-03-22 |
2019-10-10 |
Arch Oncology, Inc. |
Combination therapy for the treatment of solid and hematological cancers
|
|
WO2018183182A1
(en)
*
|
2017-03-27 |
2018-10-04 |
Celgene Corporation |
Methods and compositions for reduction of immunogenicity
|
|
JP7330942B2
(ja)
|
2017-03-31 |
2023-08-22 |
ジェンマブ ホールディング ビー．ブイ． |
二重特異性抗ｃｄ３７抗体、モノクローナル抗ｃｄ３７抗体、およびそれらの使用方法
|
|
MX2019012295A
(es)
|
2017-04-14 |
2020-02-07 |
Tollnine Inc |
Polinucleotidos inmunomoduladores, conjugados de anticuerpos de los mismos y metodos para su uso.
|
|
US20190062428A1
(en)
|
2017-06-19 |
2019-02-28 |
Surface Oncology, Inc. |
Combination of anti-cd47 antibodies and cell death-inducing agents, and uses thereof
|
|
CN109096395B
(zh)
*
|
2017-06-20 |
2022-06-24 |
华兰生物工程股份有限公司 |
阻断型cd47纳米抗体及其用途
|
|
WO2018237168A1
(en)
|
2017-06-21 |
2018-12-27 |
The Board Of Trustees Of The Leland Stanford Junior University |
Dosing parameters for cd47 targeting therapies to hematologic malignancies
|
|
EP3747438A1
(en)
*
|
2017-07-24 |
2020-12-09 |
Stichting Het Nederlands Kanker Instituut- Antoni van Leeuwenhoek Ziekenhuis |
Treating pathological conditions by direct and indirect targeting of sirpa - cd47 interaction
|
|
JP7262440B2
(ja)
*
|
2017-08-02 |
2023-04-21 |
フェインズ セラピューティクス，インコーポレーテッド |
抗ｃｄ４７抗体及びその使用
|
|
CN109422811A
(zh)
*
|
2017-08-29 |
2019-03-05 |
信达生物制药(苏州)有限公司 |
抗cd47抗体及其用途
|
|
CN108503708B
(zh)
*
|
2017-09-01 |
2021-07-30 |
北京智仁美博生物科技有限公司 |
抗人cd47抗体及其用途
|
|
EA039662B1
(ru)
|
2017-10-03 |
2022-02-24 |
Закрытое Акционерное Общество "Биокад" |
Антитела, специфичные к cd47 и pd-l1
|
|
WO2019090355A1
(en)
*
|
2017-11-06 |
2019-05-09 |
Children's National Medical Center |
Cells expressing antibodies and methods of treatment using the same
|
|
WO2019091473A1
(en)
*
|
2017-11-10 |
2019-05-16 |
I-Mab Biopharma Co., Ltd. |
Fusion proteins containing cd47 antibodies and cytokines
|
|
SG11202004864TA
(en)
|
2017-12-01 |
2020-06-29 |
Seattle Genetics Inc |
Cd47 antibodies and uses thereof for treating cancer
|
|
CA3087841A1
(en)
|
2018-01-12 |
2019-07-18 |
Aurigene Discovery Technologies Limited |
1,2,4-oxadiazole compounds as inhibitors of cd47 signalling pathways
|
|
AU2019235626A1
(en)
*
|
2018-03-13 |
2020-10-08 |
Pfizer Inc. |
Combination of CD47 blockade therapy and a CD38 antibody
|
|
GB201804860D0
(en)
|
2018-03-27 |
2018-05-09 |
Ultrahuman Two Ltd |
CD47 Binding agents
|
|
CN110305212A
(zh)
*
|
2018-03-27 |
2019-10-08 |
信达生物制药(苏州)有限公司 |
抗cd47抗体及其用途
|
|
WO2019200357A1
(en)
*
|
2018-04-12 |
2019-10-17 |
Surface Oncology, Inc. |
Biomarker for cd47 targeting therapeutics and uses therefor
|
|
CN110538321B
(zh)
*
|
2018-05-29 |
2023-03-10 |
江苏恒瑞医药股份有限公司 |
一种cd47抗体药物组合物及其用途
|
|
CN110577597B
(zh)
|
2018-06-11 |
2021-10-22 |
康诺亚生物医药科技（成都）有限公司 |
一种阻断CD47和SIRPα相互作用的抗体
|
|
US11634490B2
(en)
|
2018-06-15 |
2023-04-25 |
Accurus Biosciences, Inc. |
Blocking antibodies against CD47 and methods of use thereof
|
|
JP2021529219A
(ja)
*
|
2018-07-05 |
2021-10-28 |
トリカン・バイオテクノロジー・カンパニー・リミテッドＴｒｉｃａｎ Ｂｉｏｔｅｃｈｎｏｌｏｇｙ Ｃｏ．， Ｌｔｄ |
ヒト抗ｃｄ４７抗体およびその使用
|
|
EP3845561A4
(en)
*
|
2018-08-31 |
2022-07-06 |
Nanjing Sanhome Pharmaceutical Co., Ltd. |
ANTI-CD47 ANTIBODIES AND ITS USE
|
|
US20210338681A1
(en)
*
|
2018-10-01 |
2021-11-04 |
Secura Bio, Inc. |
Combination therapies
|
|
US12331320B2
(en)
|
2018-10-10 |
2025-06-17 |
The Research Foundation For The State University Of New York |
Genome edited cancer cell vaccines
|
|
CN113260632A
(zh)
*
|
2018-10-29 |
2021-08-13 |
蒂嘉特克斯公司 |
包含IgA抗体构建体的组合物和方法
|
|
GB2593632B
(en)
|
2018-10-29 |
2023-05-24 |
Umc Utrecht Holding Bv |
IGA mediated killing of aberrant cells by CD47-Sirpalpha checkpoint inhibition of neutrophils
|
|
EP3876931A1
(en)
|
2018-11-08 |
2021-09-15 |
Aurigene Discovery Technologies Limited |
Combination of small molecule cd-47 inhibitors with other anti-cancer agents
|
|
CN109224079B
(zh)
*
|
2018-11-26 |
2020-08-04 |
中国药科大学 |
Dna甲基转移酶抑制剂与抗cd47抗体联合用于制备抗肿瘤药物的医药用途
|
|
JP2022521624A
(ja)
*
|
2019-02-26 |
2022-04-11 |
イノベント バイオロジックス （スウツォウ） カンパニー，リミテッド |
抗ｃｄ４７抗体を含む製剤、その調製方法および使用
|
|
TW202104260A
(zh)
|
2019-04-05 |
2021-02-01 |
美商西建公司 |
腫瘤選擇性結合ｃｄ４７之抗體之工程
|
|
WO2020215012A1
(en)
*
|
2019-04-18 |
2020-10-22 |
Qlsf Biotherapeutics Inc. |
Antibodies that target human cd47
|
|
US20200400662A1
(en)
|
2019-06-07 |
2020-12-24 |
ALX Oncology Inc. |
Methods and reagents for reducing the interference of drugs that bind cd47 in serological assays
|
|
CN112206320B
(zh)
*
|
2019-07-12 |
2025-02-25 |
鲁南制药集团股份有限公司 |
一种cd47单克隆抗体冻干粉制剂及其制备工艺
|
|
KR20240137107A
(ko)
|
2019-07-16 |
2024-09-19 |
길리애드 사이언시즈, 인코포레이티드 |
Hiv 백신, 및 이의 제조 및 사용 방법
|
|
PH12022550489A1
(en)
*
|
2019-09-03 |
2022-12-12 |
Akeso Biopharma Inc |
Anti-cd47 monoclonal antibody and use thereof
|
|
ES2973832T3
(es)
|
2019-10-18 |
2024-06-24 |
Forty Seven Inc |
Terapias combinadas para el tratamiento de síndromes mielodisplásicos y leucemia mieloide aguda
|
|
JP2022553410A
(ja)
*
|
2019-10-23 |
2022-12-22 |
アーチ オンコロジー，インコーポレイテッド |
固形がんおよび血液がんを処置するための併用療法
|
|
WO2021078219A1
(en)
*
|
2019-10-25 |
2021-04-29 |
Wuxi Biologics (Shanghai) Co., Ltd. |
Novel anti-cd47 antibodies and uses thereof
|
|
JP2022552748A
(ja)
|
2019-10-31 |
2022-12-19 |
フォーティ セブン， インコーポレイテッド |
抗ｃｄ４７及び抗ｃｄ２０による血液癌の治療
|
|
US20210221886A1
(en)
*
|
2019-12-05 |
2021-07-22 |
Sorrento Therapeutics, Inc. |
Compositions and Methods Comprising an Anti-CD47 Antibody in Combination with a Tumor Targeting Antibody
|
|
BR112022011795A2
(pt)
|
2019-12-20 |
2022-08-30 |
Instil Bio Uk Ltd |
Métodos para preparar e isolar uma população terapêutica de linfócitos e para tratar câncer em um indivíduo, população terapêutica de linfócitos, bolsa criopreservada, recipiente flexível, e, sistema para extração de linfócitos
|
|
IL294032A
(en)
|
2019-12-24 |
2022-08-01 |
Carna Biosciences Inc |
Compounds that regulate diacylglycerol kinase
|
|
AU2021205144A1
(en)
*
|
2020-01-09 |
2022-08-25 |
Innovent Biologics (Suzhou) Co., Ltd. |
Application of combination of anti-CD47 antibody and anti-CD20 antibody in preparation of drugs for preventing or treating tumors
|
|
TWI890283B
(zh)
|
2020-02-14 |
2025-07-11 |
美商基利科學股份有限公司 |
結合ccr8之抗體及融合蛋白及其用途
|
|
WO2021174021A1
(en)
*
|
2020-02-27 |
2021-09-02 |
Fred Hutchinson Cancer Research Center |
Tunable extended release hydrogels
|
|
CA3169523A1
(en)
|
2020-02-28 |
2021-09-02 |
Jaume Pons |
Transglutaminase-mediated conjugation
|
|
CN111454359B
(zh)
*
|
2020-03-23 |
2021-06-29 |
倍而达药业（苏州）有限公司 |
Cd47抗体或其免疫活性片段及应用
|
|
CN115916963A
(zh)
|
2020-03-27 |
2023-04-04 |
门德斯有限公司 |
白血病来源的经修饰细胞用于增强过继性细胞治疗的效力的离体用途
|
|
TWI869582B
(zh)
*
|
2020-04-10 |
2025-01-11 |
大陸商和記黃埔醫藥（上海）有限公司 |
抗ｃｄ４７抗體及其用途
|
|
CN113527484B
(zh)
*
|
2020-04-17 |
2025-03-14 |
鲁南制药集团股份有限公司 |
抗cd47单克隆抗体
|
|
CA3172092A1
(en)
*
|
2020-04-23 |
2021-10-28 |
David Cheresh |
Compositions and methods for treating cancer
|
|
WO2021259902A1
(en)
*
|
2020-06-22 |
2021-12-30 |
Morphosys Ag |
Anti-tumor combination therapy comprising anti-cd19 antibody and polypeptides blocking the sirpα-cd47 innate immune checkpoint
|
|
EP4171617A1
(en)
|
2020-06-30 |
2023-05-03 |
Mendus B.V. |
Use of leukemia-derived cells in ovarian cancer vaccines
|
|
WO2022007947A1
(zh)
*
|
2020-07-10 |
2022-01-13 |
信达生物制药(苏州)有限公司 |
抗cd47抗体或其抗原结合片段和dna甲基化转移酶抑制剂的组合及其用途
|
|
CN116648463A
(zh)
*
|
2020-09-18 |
2023-08-25 |
伊克诺斯科学公司 |
Cd47-cd38双特异性抗体
|
|
US20220196651A1
(en)
|
2020-12-06 |
2022-06-23 |
ALX Oncology Inc. |
Multimers for reducing the interference of drugs that bind cd47 in serological assays
|
|
EP4262828A1
(en)
|
2020-12-18 |
2023-10-25 |
Instil Bio (Uk) Limited |
Tumor infiltrating lymphocytes and anti-cd47 therapeutics
|
|
US12071481B2
(en)
|
2020-12-23 |
2024-08-27 |
D-10 Therapeutics, Inc. |
Anti-CD47 antibodies and uses thereof
|
|
JP2024503822A
(ja)
*
|
2021-01-05 |
2024-01-29 |
ナショナル インスティテュート オブ バイオロジカル サイエンシズ，ベイジン |
Ｇｐｃ３及びｃｄ４７を標的とする二重特異性抗体
|
|
CA3212351A1
(en)
|
2021-03-12 |
2022-09-15 |
Mendus B.V. |
Methods of vaccination and use of cd47 blockade
|
|
TW202302145A
(zh)
|
2021-04-14 |
2023-01-16 |
美商基利科學股份有限公司 |
ＣＤ４７／ＳＩＲＰα結合及ＮＥＤＤ８活化酶Ｅ１調節次單元之共抑制以用於治療癌症
|
|
EP4322937A1
(en)
|
2021-04-14 |
2024-02-21 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
New method to improve the anti-tumoral activity of macrophages
|
|
JP7651018B2
(ja)
|
2021-06-23 |
2025-03-25 |
ギリアード サイエンシーズ， インコーポレイテッド |
ジアシルグリセロールキナーゼ調節化合物
|
|
AU2022299051B2
(en)
|
2021-06-23 |
2025-03-13 |
Gilead Sciences, Inc. |
Diacylglyercol kinase modulating compounds
|
|
MX2023014762A
(es)
|
2021-06-23 |
2024-01-15 |
Gilead Sciences Inc |
Compuestos moduladores de diacilglicerol quinasa.
|
|
JP7686091B2
(ja)
|
2021-06-23 |
2025-05-30 |
ギリアード サイエンシーズ， インコーポレイテッド |
ジアシルグリセロールキナーゼ調節化合物
|
|
EP4365197A4
(en)
*
|
2021-06-30 |
2025-05-14 |
Innobation Bio Co., Ltd. |
Humanized antibody specific to CD47 and pharmaceutical composition containing it for the prevention or treatment of CD47-mediated disease
|
|
AU2022375782B2
(en)
|
2021-10-28 |
2026-02-26 |
Gilead Sciences, Inc. |
Pyridizin-3(2h)-one derivatives
|
|
JP7787991B2
(ja)
|
2021-10-29 |
2025-12-17 |
ギリアード サイエンシーズ， インコーポレイテッド |
Ｃｄ７３化合物
|
|
US12122764B2
(en)
|
2021-12-22 |
2024-10-22 |
Gilead Sciences, Inc. |
IKAROS zinc finger family degraders and uses thereof
|
|
KR20240123836A
(ko)
|
2021-12-22 |
2024-08-14 |
길리애드 사이언시즈, 인코포레이티드 |
이카로스 아연 핑거 패밀리 분해제 및 이의 용도
|
|
TW202340168A
(zh)
|
2022-01-28 |
2023-10-16 |
美商基利科學股份有限公司 |
Ｐａｒｐ７抑制劑
|
|
WO2023178181A1
(en)
|
2022-03-17 |
2023-09-21 |
Gilead Sciences, Inc. |
Ikaros zinc finger family degraders and uses thereof
|
|
KR20240165995A
(ko)
|
2022-03-24 |
2024-11-25 |
길리애드 사이언시즈, 인코포레이티드 |
Trop-2 발현 암의 치료를 위한 병용요법
|
|
KR20240162568A
(ko)
*
|
2022-03-25 |
2024-11-15 |
우시 바이올로직스 아일랜드 리미티드 |
항-her2/항-cd47 분자 및 이의 용도
|
|
TWI876305B
(zh)
|
2022-04-05 |
2025-03-11 |
美商基利科學股份有限公司 |
用於治療結腸直腸癌之組合療法
|
|
CR20240451A
(es)
|
2022-04-21 |
2024-12-04 |
Gilead Sciences Inc |
Compuestos de modulación de kras g12d
|
|
KR20250028371A
(ko)
|
2022-07-01 |
2025-02-28 |
길리애드 사이언시즈, 인코포레이티드 |
Cd73 화합물
|
|
CA3259040A1
(en)
|
2022-07-12 |
2024-01-18 |
Gilead Sciences, Inc. |
HIV Immunogenic Polypeptides and Vaccines and Their Uses
|
|
WO2024064668A1
(en)
|
2022-09-21 |
2024-03-28 |
Gilead Sciences, Inc. |
FOCAL IONIZING RADIATION AND CD47/SIRPα DISRUPTION ANTICANCER COMBINATION THERAPY
|
|
WO2024121311A1
(en)
*
|
2022-12-07 |
2024-06-13 |
Ichnos Sciences SA |
Cd47/cd38 bispecific antibodies and methods of use to treat leukemia
|
|
AU2023409398A1
(en)
|
2022-12-22 |
2025-06-05 |
Gilead Sciences, Inc. |
Prmt5 inhibitors and uses thereof
|
|
EP4637816A1
(en)
*
|
2022-12-22 |
2025-10-29 |
The Medical College of Wisconsin, Inc. |
Compositions that target cd138 and cd3 and methods of making and using the same
|
|
AU2024252725A1
(en)
|
2023-04-11 |
2025-11-06 |
Gilead Sciences, Inc. |
Kras modulating compounds
|
|
CR20250446A
(es)
|
2023-04-21 |
2025-12-02 |
Gilead Sciences Inc |
Inhibidores de prmt5 y usos de los mismos
|
|
AU2024306338A1
(en)
|
2023-06-30 |
2026-01-08 |
Gilead Sciences, Inc. |
Kras modulating compounds
|
|
WO2025024309A2
(en)
*
|
2023-07-21 |
2025-01-30 |
The Board Of Trustees Of The Leland Stanford Junior University |
Modulation of myeloid fcυ receptor depletion
|
|
CN121620513A
(zh)
|
2023-07-26 |
2026-03-06 |
吉利德科学公司 |
Parp7抑制剂
|
|
KR20260046403A
(ko)
|
2023-07-26 |
2026-04-07 |
길리애드 사이언시즈, 인코포레이티드 |
Parp7 저해제
|
|
US20250109147A1
(en)
|
2023-09-08 |
2025-04-03 |
Gilead Sciences, Inc. |
Kras g12d modulating compounds
|
|
US20250101042A1
(en)
|
2023-09-08 |
2025-03-27 |
Gilead Sciences, Inc. |
Kras g12d modulating compounds
|
|
US20250154172A1
(en)
|
2023-11-03 |
2025-05-15 |
Gilead Sciences, Inc. |
Prmt5 inhibitors and uses thereof
|
|
WO2025137640A1
(en)
|
2023-12-22 |
2025-06-26 |
Gilead Sciences, Inc. |
Azaspiro wrn inhibitors
|
|
WO2025245003A1
(en)
|
2024-05-21 |
2025-11-27 |
Gilead Sciences, Inc. |
Prmt5 inhibitors and uses thereof
|
|
US20260098049A1
(en)
|
2024-08-12 |
2026-04-09 |
Gilead Sciences, Inc. |
Kras modulating compounds
|